FDA approves first immunotherapy drug for breast cancer

FDA approves first immunotherapy drug for breast cancer

(HealthDay)—The U.S. Food and Drug Administration has given its blessing to the first immunotherapy regimen for breast cancer.

The combination of immunotherapy (Tecentriq) and chemotherapy (Abraxane) was given accelerated approval for triple-negative that is locally advanced or has metastasized, cannot be surgically removed, and is programmed death-ligand 1-postive, CNN reported.

A study published last October in the New England Journal of Medicine revealed a median progression-free survival of 7.4 months among patients who received the combination therapy compared with 4.8 months among those who received chemotherapy with a placebo, the FDA said Friday. The study was funded by Genentech Inc., the maker of Tecentriq.

"This is the first time immunotherapy has worked in such a difficult to treat cancer, and is a huge step forward for these ," study author Peter Schmid, M.D., Ph.D., from the Queen Mary University of London, said in a statement last October, CNN reported.

More information: CNN Article
Abstract/Full Text
More Information

Journal information: New England Journal of Medicine

Copyright © 2018 HealthDay. All rights reserved.

Citation: FDA approves first immunotherapy drug for breast cancer (2019, March 12) retrieved 17 May 2024 from https://medicalxpress.com/news/2019-03-fda-immunotherapy-drug-breast-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Some patients with metastatic triple negative breast cancer live longer with immunotherapy


Feedback to editors